{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T15:39:32Z","timestamp":1721489972981},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The empirical prescription of antibiotics to inpatients with Coronavirus Disease 2019 (COVID-19) is frequent despite uncommon bacterial coinfections. Current knowledge of the effect of antibiotics on the survival of hospitalized children with COVID-19 is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To characterize the survival experience of children with laboratory-positive COVID-19 in whom antibiotics were prescribed at hospital admission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study was conducted in Mexico, with children hospitalized due to COVID-19 from March 2020 to December 2021. Data from 1601 patients were analyzed using the Kaplan\u2013Meier method and the log-rank test. We computed hazard ratios (HR) and 95% confidence intervals (CI) to evaluate the effect of the analyzed exposures on disease outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Antibiotics were prescribed to 13.2% (<jats:inline-formula><jats:alternatives><jats:tex-math>$$n$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mi>n<\/mml:mi>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> = 211) of enrolled children and a higher mortality rate [14.9 (95% CI 10.1\u201319.8) vs. 8.3 (95% CI 6.8\u20139.8)] per 1000 person-days, <jats:inline-formula><jats:alternatives><jats:tex-math>$$p$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mi>p<\/mml:mi>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> &lt; 0.001) was found among them. At any given cut-off, survival functions were lower in antibiotic-positive inpatients (<jats:inline-formula><jats:alternatives><jats:tex-math>$$p$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mi>p<\/mml:mi>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> &lt; 0.001). In the multiple model, antibiotic prescription was associated with a 50% increase in the risk of fatal outcome (HR\u2009=\u20091.50, 95% CI 1.01\u20132.22). A longer interval between illness onset and healthcare-seeking and pneumonia at hospital admission was associated with a poorer prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggest that antibiotic prescription in children hospitalized due to COVID-19 is associated with decreased survival. If later replicated, these findings highlight the need for rational antibiotics in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07516-x","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T16:20:01Z","timestamp":1654878001000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Decreased survival in children inpatients with COVID-19 and antibiotic prescription"],"prefix":"10.1186","volume":"22","author":[{"given":"Efr\u00e9n","family":"Murillo-Zamora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X\u00f3chitl","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"R\u00edos-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustin","family":"Lugo-Radillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Mendoza-Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"6","key":"7516_CR1","first-page":"516","volume":"156","author":"R Rivas-Ruiz","year":"2020","unstructured":"Rivas-Ruiz R, et al. Factors associated with death in children with COVID-19 in Mexico. Gac Med Mex. 2020;156(6):516\u201322.","journal-title":"Gac Med Mex"},{"key":"7516_CR2","unstructured":"Government of Mexico. COVID-19 in Mexico. General data [updated 2022 Jan 20]. Accessed 21 Jan 2022. [Webpage in Spanish]."},{"key":"7516_CR3","unstructured":"Johns Hopkins, University of Medicine. Coronavirus resource center: mortality analyses [Updated 2022 Apr 21]. Available at: https:\/\/coronavirus.jhu.edu\/data\/mortality. Accessed 21 Apr 2022."},{"issue":"1","key":"7516_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/MCC.0000000000000904","volume":"28","author":"C Mega","year":"2022","unstructured":"Mega C, et al. Protective ventilation in patients with acute respiratory distress syndrome related to COVID-19: always, sometimes or never? Curr Opin Crit Care. 2022;28(1):51\u20136.","journal-title":"Curr Opin Crit Care"},{"issue":"9","key":"7516_CR5","first-page":"2459","volume":"71","author":"TM Rawson","year":"2020","unstructured":"Rawson TM, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459\u201368.","journal-title":"Clin Infect Dis"},{"issue":"18","key":"7516_CR6","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"7516_CR7","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2213-2600(20)30071-0","volume":"8","author":"J Zhang","year":"2020","unstructured":"Zhang J, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8(3):e11\u20132.","journal-title":"Lancet Respir Med"},{"issue":"10229","key":"7516_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"issue":"12","key":"7516_CR9","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","volume":"26","author":"BJ Langford","year":"2020","unstructured":"Langford BJ, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"7516_CR10","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1093\/jac\/dkaa326","volume":"75","author":"B Beovic","year":"2020","unstructured":"Beovic B, et al. Antibiotic use in patients with COVID-19: a \u2018snapshot\u2019 Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"7516_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/antibiotics11010105","volume":"11","author":"K Chowdhury","year":"2022","unstructured":"Chowdhury K, et al. Management of children admitted to hospitals across Bangladesh with suspected or confirmed COVID-19 and the implications for the future: a nationwide cross-sectional study. Antibiotics (Basel). 2022;11(1):105.","journal-title":"Antibiotics (Basel)"},{"key":"7516_CR12","unstructured":"Health Ministry and General Directorate of Epidemiology of Mexico. Standardized guidelines for the epidemiological and laboratory surveillance of viral respiratory diseases [Updated 2022 Jan 19]. Available at: https:\/\/coronavirus.gob.mx\/wp-content\/uploads\/2022\/01\/2022.01.12-Lineamiento_VE_ERV_DGE.pdf. Accessed 27 Jan 2022."},{"key":"7516_CR13","unstructured":"Government of Mexico. Clinical guidelines for the treatment of COVID-19 in Mexico [Updated 2021 Aug 2]. Available at: https:\/\/coronavirus.gob.mx\/wp-content\/uploads\/2021\/08\/GuiaTx_COVID19_ConsensoInterinstitucional_2021.08.03.pdf. Accessed 03 Feb 2022. [Webpage in Spanish]."},{"key":"7516_CR14","unstructured":"General Directorate of Epidemiology of Mexico. Genomic surveillance report of the SARS-CoV-2 virus in Mexico. National and state distribution of variants as of April 04, 2022. Available at: https:\/\/coronavirus.gob.mx\/wp-content\/uploads\/2022\/04\/2022.04.04-Varientes-COVID-MX.pdf. Accessed 22 Apr 2022. [Online document in Spanish]."},{"issue":"1","key":"7516_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s12879-020-05408-6","volume":"20","author":"E Murillo-Zamora","year":"2020","unstructured":"Murillo-Zamora E, et al. Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease. BMC Infect Dis. 2020;20(1):674.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"7516_CR16","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/apa.15847","volume":"110","author":"A Yock-Corrales","year":"2021","unstructured":"Yock-Corrales A, et al. High rates of antibiotic prescriptions in children with COVID-19 or multisystem inflammatory syndrome: a multinational experience in 990 cases from Latin America. Acta Paediatr. 2021;110(6):1902\u201310.","journal-title":"Acta Paediatr"},{"issue":"10","key":"7516_CR17","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1093\/cid\/ciaa1239","volume":"72","author":"VM Vaughn","year":"2021","unstructured":"Vaughn VM, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021;72(10):e533\u201341.","journal-title":"Clin Infect Dis"},{"key":"7516_CR18","unstructured":"Mexican Institute of Social Security. Guidelines for the attention of SARS-CoV-2 (COVID-19) patients (April 2020). Available at: http:\/\/www.imss.gob.mx\/sites\/all\/statics\/imssBienestar\/marcoJuridico\/Guia-Pacientes-COVID19.pdf. Accessed 22 Apr 2022. [Online document in Spanish]."},{"issue":"1","key":"7516_CR19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1186\/s12879-021-06821-1","volume":"21","author":"AD Bendala Estrada","year":"2021","unstructured":"Bendala Estrada AD, et al. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infect Dis. 2021;21(1):1144.","journal-title":"BMC Infect Dis"},{"key":"7516_CR20","first-page":"CD015025","volume":"10","author":"M Popp","year":"2021","unstructured":"Popp M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;10:CD015025.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"7516_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2020.0321","volume":"81","author":"M Naja","year":"2020","unstructured":"Naja M, Wedderburn L, Ciurtin C. COVID-19 infection in children and adolescents. Br J Hosp Med (Lond). 2020;81(8):1\u201310.","journal-title":"Br J Hosp Med (Lond)"},{"key":"7516_CR22","doi-asserted-by":"publisher","first-page":"204020662096171","DOI":"10.1177\/2040206620961712","volume":"28","author":"D Poddighe","year":"2020","unstructured":"Poddighe D, Aljofan M. Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. Antivir Chem Chemother. 2020;28:2040206620961712.","journal-title":"Antivir Chem Chemother"},{"issue":"10","key":"7516_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.21037\/atm-20-3300","volume":"8","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review. Ann Transl Med. 2020;8(10):619.","journal-title":"Ann Transl Med"},{"key":"7516_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.668484","volume":"9","author":"M Borrelli","year":"2021","unstructured":"Borrelli M, et al. Coronavirus disease 2019 in children. Front Pediatr. 2021;9: 668484.","journal-title":"Front Pediatr"},{"issue":"4","key":"7516_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein LR, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334\u201346.","journal-title":"N Engl J Med"},{"issue":"6","key":"7516_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/jcm9061753","volume":"9","author":"J Baj","year":"2020","unstructured":"Baj J, et al. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020;9(6):1753.","journal-title":"J Clin Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07516-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07516-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T16:21:19Z","timestamp":1654878079000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07516-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7516"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07516-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Local Research Ethics Committee (601) of the IMSS approved this study (Approval ID: R-2020-601-015). All the legal guardians provided the informed written consent for the use of anonymized data from their children for the purposes of this research. We confirm that all experiments were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"532"}}